Participant flow

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib · Source last updated 2026-02-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles

   id

   FG000

   title

   Ripretinib

2. description

   Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.

   id

   FG001

   title

   Sunitinib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         36

      2. group Id

         FG001

         num Subjects

         24

      type

      Participants ongoing.

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         226

      2. group Id

         FG001

         num Subjects

         227

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         190

      2. group Id

         FG001

         num Subjects

         203

      comment

      Completed patients are defined as patients that are followed until death or until the sponsor terminates the study.

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         36

      2. group Id

         FG001

         num Subjects

         24

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice